Cynapsus closes Adagio acquisition

Cynapsus Therapeutics (TSX-V:CTH) has completed the acquisition of Adagio Pharmaceuticals in a share exchange, terminating a license option agreement for the intellectual property owned by Adagio concerning the APL-130277 patent rights and know-how. “Cynapsus is focused on advancing our Parkinson’s drug candidate, APL-130277, and the original patent rights and know how held by Adagio are [...]

Cannasat changes name to Cynapsus Therapeutics

Cannasat Therapeutics (TSX-V:CTH) received shareholder approval to change its corporate name to Cynapsus Therapeutics, with no change to the stock symbol. In a statement, CEO Anthony Giovinazzo said the new name, which is drawn loosely from the word “synapse,” more accurately reflects the company’s new focus and direction on treatments for central nervous system diseases [...]

Cannasat plans $2.5 million private placement

Cannasat Therapeutics (TSX-V:CTH) plans to raise $2.5 million through a brokered private placement of units priced at 10 cents each, with Wellington West Capital as lead placement agent. Each unit will consist of one common share and one-half of a warrant of Cannasat.  One warrant entitles the holder to purchase an additional common share at [...]

Cannasat batting hot streak in its CNS turnaround

First time up to bat, Anthony Giovinazzo hit what he calls a triple.  He followed that up with a single.  Now, he’s looking to park one in the bleachers. Newly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer [...]

Cannasat names Giovinazzo as CEO

Cannasat Therapeutics (TSX-V:CTH) has named Anthony Giovinazzo as president and CEO, succeeding co-founder David Hill, who will remain vice chairman and an advisor to Mr. Giovinazzo. “We are delighted that Anthony has agreed to join Cannasat and bring his extensive expertise to propel the company in its next phase of growth as a CNS clinical [...]